Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3853409 | 0.88 | GRM2 (0.69) | GRM2HTR2A | |
| SCHEMBL1818600 | 0.84 | GRM2 (0.69) | GRM2HTR2A | |
| SCHEMBL1818596 | 0.84 | GRM2 (0.69) | GRM2HTR2A | |
| SCHEMBL10960616 | 0.84 | GRM2 (0.83) | GRM2HTR2A | |
| SCHEMBL3869582 | 0.82 | GRM2 (0.79) | GRM2HTR2A | |
| SCHEMBL3861284 | 0.81 | GRM2 (0.58) | GRM2HTR2A | |
| SCHEMBL13359773 | 0.81 | GRM2 (0.64) | GRM2HTR2A | |
| SCHEMBL3855859 | 0.80 | GRM2 (0.62) | GRM2HTR2A | |
| SCHEMBL3851252 | 0.80 | GRM2 (0.63) | GRM2 | |
| SCHEMBL3851467 | 0.80 | GRM2 (0.63) | GRM2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2009-05-28 | — | — | US | disclosed |
| WO-2009004430-A1 | N-BENZYL OXAZOLIDINONES AND RELATED HETEROCYCLEIC COMPOUNDS AS POTENTIATORS OF GLUTAMATE RECEPTORS | PFIZER INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | CYP2D6, ABCG2, CYP2B6 | GRM2 4432/4885HTR2A 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.